View source for 4llu


==Structure of Pertuzumab Fab with light chain Clambda at 2.16A==
<StructureSection load='4llu' size='340' side='right'caption='[[4llu]], [[Resolution|resolution]] 2.16&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[4llu]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4LLU FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.16&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4llu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llu OCA], [https://pdbe.org/4llu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4llu RCSB], [https://www.ebi.ac.uk/pdbsum/4llu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4llu ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/S6C4R2_HUMAN S6C4R2_HUMAN] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Robust generation of IgG bispecific antibodies has been a long-standing challenge. Existing methods require extensive engineering of each individual antibody, discovery of common light chains, or complex and laborious biochemical processing. Here we combine computational and rational design approaches with experimental structural validation to generate antibody heavy and light chains with orthogonal Fab interfaces. Parental monoclonal antibodies incorporating these interfaces, when simultaneously co-expressed, assemble into bispecific IgG with improved heavy chain-light chain pairing. Bispecific IgGs generated with this approach exhibit pharmacokinetic and other desirable properties of native IgG, but bind target antigens monovalently. As such, these bispecific reagents may be useful in many biotechnological applications.

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.,Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, Hansen-Estruch C, Chamberlain AK, Truhlar SM, Conner EM, Atwell S, Kuhlman B, Demarest SJ Nat Biotechnol. 2014 Feb;32(2):191-8. doi: 10.1038/nbt.2797. Epub 2014 Jan 26. PMID:24463572<ref>PMID:24463572</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 4llu" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Atwell S]]
[[Category: Chamberlain AK]]
[[Category: Demarest SJ]]
[[Category: Guntas G]]
[[Category: Hansen-Estruch C]]
[[Category: Ho C]]
[[Category: Huang F]]
[[Category: Kuhlman B]]
[[Category: Leaver-Fay A]]
[[Category: Lewis SM]]
[[Category: Pustilnik A]]
[[Category: Sereno A]]
[[Category: Smith EM]]
[[Category: Truhlar SM]]
[[Category: Wu X]]